iqvia glp-1 prescriptions semaglutide tirzepatide q3 2024 Obesity Deep Dive: The Unparalleled Launch Success of Mounjaro and Zepbound The outlook for obesity from

From a patient and providers perspective, the official FDA shortage list unfortunately doesnt always reflect patients reality in real-time (it was never designed to do so and its not an inventory management system)

Since weight loss is just one result of these drugs, talking to many users (like Listen Labs does) is vital to understanding how consumers tastes are changing

Notably, Nicolau et al 8 reported a significant PASI reduction from 10 to 5.1 and DLQI improvement from 12.7 to 6.4 in patients with obesity without diabetes treated with liraglutide

In TRIUMPH-4, it affected 8.8% of the 9mg group and 20.9% of the 12mg group, compared to just 0.7% on placebo

These results show that semaglutide can lead to substantial weight loss for many people when used as part of a structured weight management plan that includes dietary changes and regular physical activity

Tirzepatide, as a newer compound, has even longer patent protection